期刊文献+

肺动脉高压药物治疗的新进展 被引量:7

原文传递
导出
摘要 近年来,随着国际上对肺动脉高压诊断分类的更新和药物治疗肺动脉高压研究的进展,使得本领域的临床研究成为备受关注的热点,尤其在肺动脉高压药物治疗的观念上,已从最初的单纯降低肺动脉压力发展到根据发病机制中的重要靶点进行干预,如阻止血管内皮细胞无序增生和血管重构、诱导内皮细胞凋亡等治疗上,并在临床上取得了明显的疗效。应该说,药物治疗正在发挥越来越重要的作用。现将近年药物治疗肺动脉高压的新进展概述如下。
作者 康健 于娜
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2007年第9期654-656,共3页 Chinese Journal of Tuberculosis and Respiratory Diseases
  • 相关文献

参考文献18

  • 1Takaoka S, Faul JL, Doyle R. Current therapies for pulmonary arterial hypertension. Semin Cardiothorac Vasc Anesth, 2007, 11:137-148.
  • 2Barst R J, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med, 1996, 334:296-302.
  • 3Mclaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation, 2002, 106 : 1477-1482.
  • 4Lammers AE, Hislop AA, Flynn Y, et al. Epoprostenol treatment in children with severe pulmonary hypertension. Heart, 2007, 93: 739-743.
  • 5Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from intravenous epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest, In press 2007.
  • 6Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med, 2005,172 : 1586-1589.
  • 7Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long- term epoprostenol ( prostacyclin ) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J, 1999,13:1351-1356.
  • 8Barst R J, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 2003, 41: 2119-2125.
  • 9Gessler T, Schmehl T, Hoeper MM, et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur Respir J, 2001, 17: 14-19.
  • 10Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 2002, 346: 896- 903.

二级参考文献23

  • 1Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med, 2004, 351:1425-1436.
  • 2Ten Dijke P, Goumans MJ, Itoh F, et al. Regulation of cell proliferation by Smad proteins. J Cell Physiol, 2002, 191: 1-16.
  • 3McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest, 2004, 126: 78S-92S.
  • 4Behr J, Borst MM, Winkler J, et al. A role for combination therapy in pulmonary arterial hypertension. Pneumologie, 2005, 59 : 730-735.
  • 5Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J, 2004, 24 : 1007-1010.
  • 6Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J, 2005, 26 : 858-863.
  • 7Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol, 2004, 43: 764-770.
  • 8Petkov V, Ziesche R, Mosgoeller W, et al. Aerosolized iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax, 2001,56: 734-736.
  • 9Itoh T, Nagaya N, Fujii T, et al. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med, 2004, 169: 34-38.
  • 10Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafll in patients with primary pulmonary hypertension. Circulation, 2001, 104: 1218-1222.

共引文献2

同被引文献49

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部